

Reducing Allogenic Blood Transfusion in Pediatric Scoliosis Surgery: Reporting 15 Years of a Multidisciplinary, Evidence-Based Quality Improvement Project

Global Spine Journal
2019, Vol. 9(8) 843-849
© The Author(s) 2019
Article reuse guidelines:
sagepub.com/journals-permissions
DOI: 10.1177/2192568219837488
journals.sagepub.com/home/gsj



Alastair G. Dick, FRCS¹ , Richard J. Pinder, MB MPH²,
Shirley A. Lyle, FRCS¹ , Tom Ember, FRCS¹,
Claire Mallinson, FRCA¹, and Jonathan Lucas, FRCS¹

Abstract

Study Design: Retrospective review of prospectively collected spinal surgery and transfusion databases.

Objectives: To evaluate the efficacy of a care pathway developed at our institution since 2003 with a focus on reducing the need for blood transfusions in children undergoing scoliosis correction surgery. The care pathway includes nurse-led clinics facilitating pre-operative hemoglobin optimization, intraoperative cell salvage, the use of tranexamic acid, and a transfusion criteria awareness program.

Methods: Retrospective review of our institution's prospectively recorded spinal surgery and transfusion databases including all cases of scoliosis surgery in patients 18 years and younger between 2001 and 2015.

Results: A total of 1039 procedures were included in the analysis. Overall, 24.4% of patients received a transfusion. The proportion of patients transfused was 89.2% in 2001-2003, 39.6% in 2004-2006, 16.5% in 2007-2009, 15.6% in 2010-2012, and 20.1% in 2013-2015. The volume of blood products transfused in those undergoing transfusion was 9.1 units in 2001-2003, 4.8 units in 2004-2006, 5.0 units in 2007-2009, 2.3 units in 2010-2012, and 2.1 units in 2013-2015. A multivariate logistic regression demonstrated adjusted odds ratios for the probability of receiving any transfusion of 5.45 (95% confidence interval 3.62-8.11) for patients with neuromuscular diagnoses and 11.17 (5.02-24.86) for those undergoing combined anterior and posterior surgical approach.

Conclusions: We have demonstrated over a 15-year period that the introduction of a multifaceted, multidisciplinary pathway can dramatically and sustainably reduce the need for blood transfusions and their attendant risks in pediatric scoliosis surgery. This data lends weight to the adoption of such a care pathway in pediatric scoliosis surgery.

Keywords

spinal surgery, scoliosis, transfusion, tranexamic acid, cell salvage

Introduction

Pediatric scoliosis surgery for both idiopathic and neuromuscular curves has historically been associated with large volumes of perioperative blood loss.¹ Scoliosis surgery can involve prolonged operative times with often extensive soft tissue dissection and bone cutting.² Historically up to 59% of children undergoing scoliosis surgery have received allogenic blood transfusions in the perioperative period.³ Though the risk of transmission of blood borne viruses such as human immune deficiency virus and hepatitis C virus have decreased significantly with the increased security of the blood supply,⁴ other risks of allogenic blood

transfusion remain. Transfusion induced immunomodulation can increase the risk of postoperative infection.⁵ Transfusion-related acute lung injury and mistransfusion, though rare, are

¹ Guy's & St Thomas' NHS Foundation Trust, London, UK

² Imperial College London, London, UK

Corresponding Author:

Alastair G. Dick, Department of Spinal Surgery, Guy's & St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, UK.
Email: agdick@doctors.org.uk



Summary of interventions
Pre-operative <ul style="list-style-type: none"> • Nurse led pre-operative optimisation clinic
Intra-operative <ul style="list-style-type: none"> • Tranexamic acid • Cell salvage • Optimal positioning • Posterior approach
Post-operative <ul style="list-style-type: none"> • Transfusion criteria awareness programme • Senior decision maker agreement for all transfusions

Figure 1. Summary of transfusion reduction interventions.

associated with significant morbidity and mortality.⁶ Allogenic blood transfusion is a costly treatment both financially (the cost in the UK National Health Service of a unit of red blood cells has increased from £78 in 2000 to £125 in 2011) and in the utilization of a scarce resource.^{7,8}

Multiple interventions have been employed to reduce the need for allogenic blood transfusions in scoliosis surgery.⁹ These can be divided into preoperative interventions, including hemoglobin optimization (using hematinics and erythropoietin) and autologous blood donation. Intraoperative interventions include hypotensive anesthesia, cell salvage and retransfusion, antifibrinolytic administration² and appropriate surgical techniques. Postoperative interventions include acceptance of lower hemoglobin levels without triggering transfusion.⁷

Since 2001, our unit has adopted a multifaceted, multidisciplinary blood conservation integrated care pathway program involving the introduction of some of these techniques with the objective to reduce allogenic blood transfusion rates. The goal of our study was to review the allogenic transfusion rates and transfusion volumes over the 15-year period since the introduction of the care pathway and analyze factors associated with an increased risk of transfusion.

Methods

Our pediatric spinal surgery service began in 2000 and covers a tertiary referral population of 4.5 million. Initially, the service was run by 2 surgeons: 1 with 3 years prior experience and 1 new into practice. Since 2000, the service has included 6 different surgeons and currently employs 3 surgeons. Beginning in 2003, we developed a multifaceted program aiming to reduce allogenic blood transfusion rates in children undergoing scoliosis surgery (Figures 1 and 2). In 2003, cell salvage and aprotinin administration were introduced for all scoliosis surgeries. In 2007, a nurse-led optimization clinic was introduced to review all preoperative patients with hematinics and erythropoietin administered as required to meet a target preoperative hemoglobin level of 125 g/L. This target was chosen based on a previous local review that identified this cutoff as predictive of the need for postoperative transfusion.¹⁰ In 2007, because of safety concerns, aprotinin usage was stopped and replaced with tranexamic acid. Intravenous tranexamic acid has since been used with a present dosage




Figure 2. Timeline for transfusion reduction interventions.

regime of a loading dose of 30 mg/kg followed by a 1 mg/kg/h infusion continued until skin closure. All patients receive moderate hypotensive anesthesia¹¹ and appropriate positioning to reduce abdominal compression, including the usage of a Jackson table. A transfusion awareness program was developed in 2009 to educate all health care professionals about strategies to minimize perioperative blood transfusion. Transfusion triggers were introduced in 2009: A postoperative hemoglobin threshold of 80 g/L in patients with clinical symptoms of anemia is used to consider transfusion and 70 g/L in those without clinical symptoms. Any decision to transfuse a patient must be made by a senior decision maker (consultant surgeon or anesthetist).

Our institution maintains a prospectively recorded spinal surgery database and transfusion department database. A retrospective review was undertaken of both databases to include all patients aged 18 years or younger undergoing scoliosis correction surgery between January 2001 and December 2015. Six surgeons undertook the procedures with surgical techniques evolving throughout the 15-year period. All patients underwent wide facetectomies, less than 5% underwent osteotomies, and less than 5% had postoperative wound drains (routine usage stopped in 2004).

Data analyzed included patients' demographics, underlying diagnosis, surgical approach, preoperative and lowest postoperative hemoglobin within 7 days of surgery, transfusion rates, and volumes of red blood cells and other blood products transfused. The 15-year period studied was divided into five 3-year periods for the purposes of comparison and analysis.

The collected data were analyzed using STATA version 14.0.¹² Univariate and multivariate logistic regressions were performed to identify associations between variables yielding odds ratios (OR), adjusted OR, 95% confidence intervals (CI), and *P* values. Trend (*P* trend) was calculated using linear regression. All tests were 2-sided, with a *P* value of less than .05 indicating statistical significance.

Results

Between January 2001 and December 2015, a total of 1039 scoliosis correction procedures were performed (Table 1). The median age at surgery was 14.0 years (interquartile range 13-16). Of these, 705 (67.9%) patients were female and 334 (32.2%) were male. Overall, 629 (61.1%) procedures were for idiopathic

Table 1. Baseline Characteristics of the Cohort (n = 1039).

Demographics	n	%
Age, years (n = 1039), median [IQR]	14.0	[13-16]
Age-group, years (n = 1039)		
0 to <3	13	1.3
3 to <6	22	2.1
6 to <9	35	3.4
9 to <12	86	8.3
12 to <15	386	37.2
15-18	497	47.8
Gender (n = 1039)		
Male	334	32.2
Female	705	67.9
Ethnicity (n = 891)		
White British	593	66.6
White other	96	10.8
Black	147	16.5
Asian	15	1.7
Mixed	18	2.0
Other	22	2.5
Diagnosis (n = 1029)		
Idiopathic scoliosis	629	61.1
Neuromuscular diagnoses		
Neuromuscular scoliosis	189	18.4
Cerebral palsy	72	7.0
Neurofibromatosis	21	2.0
Congenital scoliosis	20	1.9
Unique neuromuscular diagnosis	11	1.1
Muscular dystrophy	9	0.9
Prader-Willi syndrome	7	0.7
Spina bifida	5	0.5
Other	66	6.4
Surgical approach (n = 993)		
Anterior	125	12.6
Posterior	797	80.3
Combined	71	7.2
Blood results (n = 1039)		
Hemoglobin, g/L		
Preoperative (n = 995), mean (SD)	132.8	(12.5)
Postoperative lowest (n = 990), mean (SD)	96.7	(16.6)
Proportion of patients transfused (n = 1039)	253	24.4
Units of blood products transfused for those patients who were transfused, mean (SD)	4.7	(6.0)

scoliosis, 400 (38.9%) for scoliosis associated with underlying neuromuscular diagnoses (NMS). The posterior approach was used in 797 cases (80.3%), anterior in 125 (12.6%), combined anterior and posterior (including staged) in 71 (7.2%).

Overall, 253 patients (24.4%) received a blood transfusion with a mean transfusion volume of 4.7 units (SD 6.0). Full demographics of the cohort can be found in Table 1. Mean (SD in parentheses) preoperative hemoglobin was 133.8 g/L (13.5) in 2001-2003, 135.4 g/L (12.8) in 2004-2006, 132.5 g/L (12.9) in 2007-2009, 131.9 g/L (13.1) in 2010-2012, and 132.7 g/L (11.4) in 2013-2015.

The proportion of patients transfused was 89.2% in 2001-2003, 39.6% in 2004-2006, 16.5% in 2007-2009, 15.6% in 2010-2012, and 20.1% in 2013-2015 (Table 2). Figure 3 demonstrates the proportion of patients transfused per year by diagnostic category. The volume of blood products

transfused in those undergoing transfusion was 9.1 units in 2001-2003, 4.8 units in 2004-2006, 5.0 units in 2007-2009, 2.3 units in 2010-2012, and 2.1 units in 2013-2015.

Age, female gender, "white other" ethnicity, neuromuscular diagnoses, and nonanterior surgical approach were significantly associated with an increased likelihood of transfusion in the univariate model (Table 3). After adjustment, "white other" ethnicity remained associated. Black ethnicity was also associated with an increased likelihood of blood transfusion in the multivariate model.

Patients undergoing procedures for neuromuscular diagnoses were approximately 5 times more likely to receive a blood transfusion in both the univariate and multivariate regressions (adjusted OR 5.45, 95% CI 3.62-8.11). Posterior approach was associated with higher transfusion likelihood but this association was not significant in the multivariate model. Combined surgical approach was associated with an approximately 10-fold likelihood of transfusion before and after adjustment (adjusted OR 11.17, 95% CI 5.02-24.86). Sub group analysis by surgical approach demonstrated a downward trend in proportion transfused and mean volume transfused across all approaches between 2001-2003 and 2013-2015 (Table 4).

Descriptive analysis and univariate regression of the diagnoses demonstrated that unique neuromuscular diagnoses, cerebral palsy, neuromuscular scoliosis, and congenital scoliosis were strongly associated with an increased likelihood of transfusion (Table 5); additionally, all patients (n = 4) with muscular dystrophy received a transfusion.

Discussion


The aim of our study was to determine whether our unit's allogenic blood transfusion rate had reduced following the introduction of a blood conserving integrated care pathway for children undergoing scoliosis surgery. We report a significant reduction in allogenic transfusion rates from approximately 90% of patients receiving a transfusion at the start of the program to approximately 20% most recently. Several reports exist in the literature regarding reducing allogenic blood transfusion rates with the use of various blood conservation techniques in small cohorts. Verma et al¹³ reported on the introduction of a blood transfusion reduction policy resulting in an allogenic transfusion rate of 5% in 38 patients with adolescent idiopathic scoliosis (AIS). Berney et al¹⁴ reported a reduction from a 56% allogenic transfusion rate to a 0% transfusion rate in an AIS cohort of 56 patients with the usage of tranexamic acid. Hassan et al¹⁵ reported in 2011 on their 2-year experience with 104 patients with blood conservation measures similar to ours and report a 36% transfusion rate in NMS and 1.7% in AIS.¹⁵ To our knowledge, our study is the first to evaluate a blood conservation program in a large cohort (>1000 patients).

We note an especially marked reduction in transfusion rates in patients with AIS. Blood loss is known to be considerably higher in patients with NMS as compared with AIS.¹ Shaipro et al¹⁶ reported a 75% and 94% transfusion rate in patients with Duchenne muscular dystrophy undergoing scoliosis surgery with and without tranexamic acid, respectively. Meert et al³ reported an

Table 2. Demography, Surgical Approach, and Proportion of Patients Receiving a Transfusion From 2001 to 2015 in 3-Year Periods.

	2001-2003	2004-2006	2007-2009	2010-2012	2013-2015
Total procedures, %	65	111	231	314	318
Age, years, median	14	15	14	15	14
Gender, %					
Male	29.2	36.0	28.1	33.1	33.3
Female	70.8	64.0	71.9	66.9	66.7
Diagnosis, %					
Idiopathic scoliosis	59.0	67.3	64.2	60.7	57.6
Neuromuscular	41.0	32.7	35.8	39.3	42.4
Surgical approach, %					
Anterior	13.8	26.0	25.2	8.6	4.1
Posterior	36.2	52.0	72.1	86.6	94.7
Combined	50.0	22.1	2.7	4.8	1.3
Hemoglobin, g/L, mean (SD)					
Preoperative	133.8 (13.5)	135.4 (12.8)	132.5 (12.9)	131.9 (13.1)	132.7 (11.4)
Postoperative lowest	88.4 (15.8)	97.4 (14.6)	100.5 (16.2)	95.3 (17.6)	96.1 (16.2)
Patients transfused, %	89.2	39.6	16.5	15.6	20.1
Units of blood products transfused for those patients who were transfused	9.1	4.8	5.0	2.3	2.1

^aTrend of percentage of patients transfused overall each year from 2001 to 2015: *P* trend < .001.

**Figure 3.** Proportion of patients transfused per year by diagnostic category, 2001-2015.

overall allogenic transfusion rate of 59% in a mixed scoliosis cohort of 107 patients with underlying neuromuscular disease a predictor of increased transfusion requirements. We report a reduction from 96.0% in 2001-2003 to 39.6% in 2013-2015 in NMS patients compared with 86.1% in 2001-2003 to 4.9% in 2013-2015 in AIS patients. These results are broadly similar to those reported by Hassan et al.¹⁵ In 2013-2015, we note an increase in the transfusion rate for NMS patients from 30.9% to 39.6%, while in the same time period, the rate for AIS patients continued to decline from 5.8% to 4.9%. This could be due to an increasingly challenging surgical caseload with surgical intervention being undertaken in patients not previously considered surgical candidates.

Our integrated care pathway includes a range of interventions, all aimed at reducing allogenic blood transfusion rates. The cumulative effect of all the interventions is seen in our results; establishing specifically which are responsible for the benefits seen is not possible in a retrospective study. The greatest reduction in transfusion rate was seen between 2001-2003 and 2004-2006, which followed the introduction of aprotinin and cell salvage. These results suggest that aprotinin (later tranexamic acid) and cell salvage may be particularly effective in reducing transfusion rates. There is an extensive evidence base for the benefits of tranexamic acid in reducing intraoperative blood loss.¹⁶⁻²¹ A recent meta-analysis by Yuan et al² demonstrated a significant reduction in total blood loss after scoliosis surgery with tranexamic acid (though no reduction in

Table 3. Univariate and Multivariate Logistic Regression of Demographic and Surgical Characteristics Associated With the Probability of Receiving Any Blood Transfusion Between 2001 and 2015.

	Odds Ratio	(95% Confidence Interval)	Adjusted Odds Ratio ^a	(95% Confidence Interval)
Demographics				
Age	0.94	(0.90-0.98)*	1.06	(1.00-1.11)
Gender				
Male	1.00		1.00	
Female	0.68	(0.51-0.91)*	1.13	(0.78-1.64)
Ethnicity				
White	1.00		1.00	
White other	2.95	(1.89-4.59)**	2.33	(1.41-3.87)**
Black	1.16	(0.77-1.75)	1.76	(1.09-2.87)*
Asian	0.49	(0.11-2.21)	0.42	(0.89-1.96)
Mixed	2.00	(0.78-5.36)	2.88	(0.92-9.00)
Other	2.22	(0.93-5.30)	1.79	(0.67-5.05)
Diagnostic category				
Idiopathic scoliosis	1.00		1.00	
Neuromuscular diagnoses	5.17	(3.80-7.04)**	5.45	(3.62-8.11)**
Surgical approach				
Anterior	1.00		1.00	
Posterior	1.94	(1.10-3.22)*	1.64	(0.88-3.05)
Combined	9.87	(4.87-20.0)**	11.17	(5.02-24.86)**

^aThe multivariate model included age, sex, ethnicity, diagnosis, and surgical approach.
*P < .05; **P ≤ .001.

Table 4. Proportion of Patients Receiving a Transfusion and Volumes of Blood Products Transfused From 2001 to 2015 in 3-Year Periods, by Surgical Approach.

	2001-2003	2004-2006	2007-2009	2010-2012	2013-2015
Proportion of patients transfused, %					
Anterior	50.0	85.0	5.3	18.5	7.8
Posterior	95.2	52.5	20.3	15.1	20.6
Combined	96.6	47.1	33.3	20.0	25.0
Mean units of blood products transfused for those patients who were transfused					
Anterior	2.8	1.0	14.3	1.8	2.0
Posterior	10.0	5.4	4.2	2.3	2.1
Combined	10.0	3.3	4.0	3.7	1.0

the need for transfusion). The optimal dosing of intravenous tranexamic acid remains unclear. Grant et al²² found a trend toward reduced transfusion requirements in a small pediatric scoliosis cohort using high dose (20 mg/kg loading dose, 10 mg/kg/h infusion) as opposed to lower dose (10 mg/kg loading dose, 1 mg/kg/h infusion). There may be a role for topical tranexamic acid administration—a recent systematic review found limited though promising evidence for reducing blood loss in spinal surgery.²³

Evidence for the benefits of cell saver usage in scoliosis surgery remains unclear. A Cochrane systematic review in 2010 demonstrated cell saver usage to reduce allogenic transfusion rates though this was in adults and included elective cardiac surgery as well as other nonspinal orthopedic procedures.²⁴ There are conflicting reports of the benefits in terms of reducing allogenic blood transfusion requirements with cell

Table 5. Univariate Logistic Regression of Diagnosis and the Proportion of Patients Receiving Any Blood Transfusion Between 2001 and 2015.

Diagnosis	Percentage Transfused	Odds Ratio	(95% Confidence Interval)
Idiopathic scoliosis	12.4	1.00	
Neuromuscular diagnoses			
Neuromuscular scoliosis	41.8	5.07	(3.49-7.37)**
Cerebral palsy	62.5	11.77	(6.91-20.1)**
Neurofibromatosis	4.8	0.35	(0.47-2.67)
Congenital scoliosis	35.0	3.80	(1.47-9.83)*
Muscular dystrophy	100	—	
Unique neuromuscular diagnosis	72.7	18.84	(4.90-72.51)**
Prader-Willi syndrome	28.6	2.83	(0.54-14.81)
Spina bifida	40.0	4.71	(0.77-28.62)
Other	24.2	2.26	(1.23-4.16)*

*P < .05; **P ≤ .001.

saver usage.²⁵⁻²⁹ The usage of a low transfusion threshold has been shown to result in a significant reduction in risk of blood transfusion with no evidence of an increase in associated morbidity and mortality.³⁰

We have not adopted the usage of autologous blood transfusion in our integrated care pathway. Concerns remain about the risk of transmission of bacterial infection³¹ and the evidence remains conflicted as to its role in reducing allogenic transfusion.^{32,33}

Limitations

The limitations of the study are typical of those expected in retrospective studies. The quality of the data is reliant on that

recorded prospectively in the databases and some demographic data were incomplete in our dataset. There is no simultaneous control group as all patients were enrolled in the blood conservation integrated care pathway. It is not possible to control for potential confounders such as improved surgical technique and decreased operative time as surgical experience developed over the period studied.

Conclusion

Our study shows that using simple blood conservation methods can dramatically and sustainably reduce the need for allogenic blood transfusions and their attendant risks and costs in pediatric scoliosis surgery. These results lend weight to the adoption of such measures in pediatric scoliosis surgery.


Declaration of Conflicting Interests


The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

ORCID iD

Alastair G. Dick  <https://orcid.org/0000-0002-3968-4193>

Shirley A. Lyle  <https://orcid.org/0000-0001-9678-3158>

References

- Shapiro F, Sethna N. Blood loss in pediatric spine surgery. *Eur Spine J*. 2004;13(suppl 1):S6-S17. doi:10.1007/s00586-004-0760-y
- Yuan QM, Zhao ZH, Xu BS. Efficacy and safety of tranexamic acid in reducing blood loss in scoliosis surgery: a systematic review and meta-analysis. *Eur Spine J*. 2017;26:131-139. doi:10.1007/s00586-016-4899-0
- Meert KL, Kannan S, Mooney JF. Predictors of red cell transfusion in children and adolescents undergoing spinal fusion surgery. *Spine (Phila Pa 1976)*. 2002;27:2137-2142. doi:10.1097/01.BRS.0000025691.54848.D0
- Busch MP, Kleinman SH, Nemo GJ. Current and emerging infectious risks of blood transfusions. *JAMA*. 2003;289:959-962. doi:10.1001/jama.289.8.959
- Hill GE, Frawley WH, Griffith KE, Forestner JE, Minei JP. Allogeneic blood transfusion increases the risk of postoperative bacterial infection: a meta-analysis. *J Trauma*. 2003;54:908-914. doi:10.1097/01.TA.0000022460.21283.53
- Madjdpour C, Spahn DR. Allogeneic red blood cell transfusions: efficacy, risks, alternatives and indications. *Br J Anaesth*. 2005;95:33-42. doi:10.1093/bja/ae290
- Spahn DR, Casutt M. Eliminating blood transfusions: new aspects and perspectives. *Anesthesiology*. 2000;93:242-255.
- Ker K, Edwards P, Perel P, Shakur H, Roberts I. Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. *BMJ*. 2012;344:e3054. doi:10.1136/bmj.e3054
- Oetgen ME, Litrenta J. Perioperative blood management in pediatric spine surgery. *J Am Acad Orthop Surg*. 2017;25:480-488. doi:10.5435/JAAOS-D-16-00035
- Pinder R, Mallinson C, Lucas J, Lyle S. A multi-disciplinary approach to improving blood transfusion practice in paediatric scoliosis correction surgery. Poster presented at: EFORT Congress; May 23-25, 2012; Berlin, Germany. http://www.efort.org/berlin2012/download/EFORT2012_BERLIN_BOOK_V1.8_20120502.pdf.
- Raw DA, Beattie JK, Hunter JM. Anaesthesia for spinal surgery in adults. *Br J Anaesth*. 2003;91:886-904. doi:10.1093/bja/aeg253
- StataCorp. *Stata Statistical Software: Release 14*. College Station, TX: StataCorp LP; 2015.
- Verma RR, Williamson JB, Dashti H, Patel D, Oxborrow NJ. Homologous blood transfusion is not required in surgery for adolescent idiopathic scoliosis. *J Bone Joint Surg Br*. 2006;88:1187-1191. doi:10.1302/0301-620X.88B9.17708
- Berney MJ, Dawson PH, Phillips M, Lui DF, Connolly P. Eliminating the use of allogeneic blood products in adolescent idiopathic scoliosis surgery. *Eur J Orthop Surg Traumatol*. 2015;25(suppl 1):S219-S223. doi:10.1007/s00590-015-1624-3
- Hassan N, Halanski M, Wincek J, et al. Blood management in pediatric spinal deformity surgery: review of a 2-year experience. *Transfusion*. 2011;51:2133-2141. doi:10.1111/j.1537-2995.2011.03175.x
- Shapiro F, Zurakowski D, Sethna NF. Tranexamic acid diminishes intraoperative blood loss and transfusion in spinal fusions for Duchenne muscular dystrophy scoliosis. *Spine (Phila Pa 1976)*. 2007;32:2278-2283. doi:10.1097/BRS.0b013e31814cf139
- Neilipovitz DT, Murto K, Hall L, Barrowman NJ, Splinter WM. A randomized trial of tranexamic acid to reduce blood transfusion for scoliosis surgery. *Anesth Analg*. 2001;93:82-87. doi:10.1097/00132586-200204000-00034
- Sethna NF, Zurakowski D, Brustowicz RM, Bacsik J, Sullivan LJ, Shapiro F. Tranexamic acid reduces intraoperative blood loss in pediatric patients undergoing scoliosis surgery. *Anesthesiology*. 2005;102:727-732. doi:10.1097/00000542-200504000-00006
- Yagi M, Hasegawa J, Nagoshi N, et al. Does the intraoperative tranexamic acid decrease operative blood loss during posterior spinal fusion for treatment of adolescent idiopathic scoliosis? *Spine (Phila Pa 1976)*. 2012;37:E1336-E1342. doi:10.1097/BRS.0b013e318266b6e5
- Dhawale AA, Shah SA, Sponseller PD, et al. Are antifibrinolytics helpful in decreasing blood loss and transfusions during spinal fusion surgery in children with cerebral palsy scoliosis? *Spine (Phila Pa 1976)*. 2012;37:E549-E555. doi:10.1097/BRS.0b013e31823d009b
- Neilipovitz DT. Tranexamic acid for major spinal surgery. *Eur Spine J*. 2004;13(suppl 1):S62-S65. doi:10.1007/s00586-004-0716-2
- Grant JA, Howard J, Luntley J, Harder J, Aleissa S, Parsons D. Perioperative blood transfusion requirements in pediatric scoliosis surgery: the efficacy of tranexamic acid. *J Pediatr Orthop*. 2009;29:300-304. doi:10.1097/BPO.0b013e31819a85de

23. Winter SF, Santaguida C, Wong J, Fehlings MG. Systemic and topical use of tranexamic acid in spinal surgery: a systematic review. *Global Spine J.* 2016;6:284-295. doi:10.1055/s-0035-1563609
24. Carless PA, Henry DA, Moxey AJ, O'connell DL, Brown T, Fergusson DA. Cell salvage for minimising perioperative allogeneic blood transfusion. *Cochrane Database Syst Rev.* 2006;(4):CD001888. doi:10.1002/14651858.CD001888.pub2
25. Miao YL, Ma HS, Guo WZ, et al. The efficacy and cost-effectiveness of cell saver use in instrumented posterior correction and fusion surgery for scoliosis in school-aged children and adolescents. *PLoS One.* 2014;9:e92997. doi:10.1371/journal.pone.0092997
26. Akgül T, Dikici F, Ekinici M, Buget M, Polat G, Şar C. The efficacy of cell saver method in the surgical treatment of adolescent idiopathic scoliosis. *Acta Orthop Traumatol Turc.* 2014;48:303-306. doi:10.3944/AOTT.2014.13.0146
27. Bowen RE, Gardner S, Scaduto AA, Eagan M, Beckstead J. Efficacy of intraoperative cell salvage systems in pediatric idiopathic scoliosis patients undergoing posterior spinal fusion with segmental spinal instrumentation. *Spine (Phila Pa 1976).* 2010;35:246-251. doi:10.1097/BRS.0b013e3181bdf22a
28. Ersen O, Ekinici S, Bilgic S, Kose O, Oguz E, Sehirlioglu A. Posterior spinal fusion in adolescent idiopathic scoliosis with or without intraoperative cell salvage system: a retrospective comparison. *Musculoskelet Surg.* 2012;96:107-110. doi:10.1007/s12306-012-0203-6
29. Liang J, Shen J, Chua S, et al. Does intraoperative cell salvage system effectively decrease the need for allogeneic transfusions in scoliotic patients undergoing posterior spinal fusion? A prospective randomized study. *Eur Spine J.* 2015;24:270-275. doi:10.1007/s00586-014-3282-2
30. Carson JL, Stanworth SJ, Roubinian N, et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. *Cochrane Database Syst Rev.* 2016;10:CD002042. doi:10.1002/14651858.CD002042.pub4
31. Blajchman MA. Bacterial contamination of cellular blood components: risks, sources and control. *Vox Sang.* 2004;87(suppl 1):98-103.
32. Ridgeway S, Tai C, Alton P, Barnardo P, Harrison DJ. Pre-donated autologous blood transfusion in scoliosis surgery. *J Bone Joint Surg Br.* 2003;85:1032-1036. doi:10.1302/0301-620X.85B7.13466
33. García-Erce JA, Solano VM, Cuenca J, et al. Predeposit autologous donation in spinal surgery: a multicentre study. *Haemost Spine Surg.* 2005;13:34-39. doi:10.1007/3-540-27394-8_6